Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660306 | 0.83 | MAPT (0.45) | — | |
| SCHEMBL12695037 | 0.83 | USP2 (0.44) | — | |
| SCHEMBL21267710 | 0.83 | HRH3 (0.41) | — | |
| SCHEMBL17660305 | 0.82 | MAPT (0.46) | CDK4CDK2CCNA2CCND1CDK6 | |
| SCHEMBL21266987 | 0.82 | HRH3 (0.43) | CDK4CDK2CCNA2CCND1GSK3B | |
| SCHEMBL14307264 | 0.81 | ACVR1 (0.46) | CDK4CDK2CCNA2CCND1CCNA1 | |
| SCHEMBL23103862 | 0.81 | HRH3 (0.40) | — | |
| SCHEMBL23108854 | 0.81 | HRH3 (0.40) | — | |
| SCHEMBL23103165 | 0.81 | HRH3 (0.40) | — | |
| SCHEMBL21267364 | 0.80 | CDK4 (0.40) | CDK4CDK2CCNA2CCND1CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CDK4 1/4885CDK2 6/4885CCNA2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.